MEP32208A - Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients - Google Patents

Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Info

Publication number
MEP32208A
MEP32208A MEP-322/08A MEP32208A MEP32208A ME P32208 A MEP32208 A ME P32208A ME P32208 A MEP32208 A ME P32208A ME P32208 A MEP32208 A ME P32208A
Authority
ME
Montenegro
Prior art keywords
active ingredients
combination
agonist
lasting
beta2
Prior art date
Application number
MEP-322/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Roberta Razzetti
Fiorella Pastore
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP32208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MEP32208A publication Critical patent/MEP32208A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-322/08A 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients MEP32208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03004184A EP1452179A1 (en) 2003-02-27 2003-02-27 Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
PCT/EP2004/001960 WO2004075896A1 (en) 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
YUP-2005/0615A RS20050615A (xx) 2003-02-27 2004-02-27 Lek koji sadrži visoko potentni dugotrajni beta2-agonist u kombinaciji sa drugim aktivnim sastojcima

Publications (1)

Publication Number Publication Date
MEP32208A true MEP32208A (en) 2010-10-10

Family

ID=32748803

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-322/08A MEP32208A (en) 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Country Status (32)

Country Link
US (1) US20070020190A1 (xx)
EP (3) EP1452179A1 (xx)
JP (1) JP2006519204A (xx)
KR (1) KR20050104367A (xx)
CN (2) CN100370986C (xx)
AR (1) AR043419A1 (xx)
AT (1) ATE401887T1 (xx)
AU (1) AU2004216472B2 (xx)
BR (1) BRPI0408047A (xx)
CA (1) CA2517321A1 (xx)
CY (1) CY1108360T1 (xx)
DE (1) DE602004015260D1 (xx)
DK (1) DK1603565T3 (xx)
EA (1) EA008828B1 (xx)
ES (1) ES2309503T3 (xx)
HK (1) HK1087009A1 (xx)
HR (1) HRP20050726A2 (xx)
MA (1) MA27630A1 (xx)
ME (1) MEP32208A (xx)
MX (1) MXPA05009007A (xx)
NO (1) NO20053959L (xx)
NZ (1) NZ541997A (xx)
PE (1) PE20050290A1 (xx)
PL (1) PL377814A1 (xx)
PT (1) PT1603565E (xx)
RS (1) RS20050615A (xx)
SA (1) SA04250122B1 (xx)
SI (1) SI1603565T1 (xx)
TN (1) TNSN05186A1 (xx)
UA (1) UA82217C2 (xx)
WO (1) WO2004075896A1 (xx)
ZA (1) ZA200506820B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1670482B2 (en) 2003-09-16 2022-06-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
WO2006105401A2 (en) * 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
JP2009502997A (ja) * 2005-08-01 2009-01-29 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 噴霧投与用の長時間作用型ベータ２−アゴニストを含む医薬製剤
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
AU2006329042B2 (en) * 2005-12-21 2012-02-02 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
JP2010526763A (ja) * 2006-05-24 2010-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患を治療するための新規な長時間作用型の薬剤組成物
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
CA2763402A1 (en) * 2009-05-25 2010-12-02 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
EP2563364A1 (en) * 2010-04-26 2013-03-06 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
EP3871676A1 (en) 2010-07-16 2021-09-01 Cipla Limited Pharmaceutical compositions comprising r(+) budesonide and arformoterol
WO2012010854A1 (en) 2010-07-23 2012-01-26 Cipla Limited Inhalation formulations comprising carmoterol in combination with a corticosteroid
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
HUE037275T2 (hu) * 2013-03-15 2018-08-28 Verona Pharma Plc Gyógyszer-kombináció
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
ES2895850T3 (es) * 2014-11-24 2022-02-22 Univ Illinois Procedimiento de prevención o tratamiento de una enfermedad o afección pulmonar
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP2036544B1 (en) * 1997-03-20 2016-12-28 Merck Sharp & Dohme Corp. Dosage form of powder agglomerates
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
SK286694B6 (sk) * 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
CA2517321A1 (en) 2004-09-10
US20070020190A1 (en) 2007-01-25
CN101244063A (zh) 2008-08-20
AU2004216472A1 (en) 2004-09-10
EA200501108A1 (ru) 2006-04-28
KR20050104367A (ko) 2005-11-02
NO20053959L (no) 2005-11-28
HK1087009A1 (en) 2006-10-06
ES2309503T3 (es) 2008-12-16
RS20050615A (xx) 2007-09-21
WO2004075896A1 (en) 2004-09-10
EP1834643A3 (en) 2007-10-24
PE20050290A1 (es) 2005-05-26
UA82217C2 (uk) 2008-03-25
EP1834643A2 (en) 2007-09-19
NZ541997A (en) 2008-12-24
EP1452179A1 (en) 2004-09-01
AU2004216472B2 (en) 2009-08-06
CN100370986C (zh) 2008-02-27
PL377814A1 (pl) 2006-02-20
BRPI0408047A (pt) 2006-02-14
PT1603565E (pt) 2008-10-06
SA04250122B1 (ar) 2009-03-11
JP2006519204A (ja) 2006-08-24
DE602004015260D1 (de) 2008-09-04
EP1603565A1 (en) 2005-12-14
ATE401887T1 (de) 2008-08-15
AR043419A1 (es) 2005-07-27
TNSN05186A1 (en) 2007-06-11
MA27630A1 (fr) 2005-11-01
CY1108360T1 (el) 2014-02-12
HRP20050726A2 (en) 2006-02-28
EP1603565B1 (en) 2008-07-23
SI1603565T1 (sl) 2008-10-31
DK1603565T3 (da) 2008-11-10
CN1753678A (zh) 2006-03-29
NO20053959D0 (no) 2005-08-25
ZA200506820B (en) 2006-11-29
EA008828B1 (ru) 2007-08-31
MXPA05009007A (es) 2005-10-18

Similar Documents

Publication Publication Date Title
MEP32208A (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
HUP0203586A2 (hu) Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja
HUP0400659A2 (hu) Kitinázokkal, kitinázszerű molekulákkal és gyulladásos megbetegedéssel kapcsolatos eljárások, készítmények és reagenskészletek
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
BRPI0110947B8 (pt) processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
MXPA02011311A (es) Composicion novedosa.
MXPA04003675A (es) Composicion estable que comprende particulas en una matriz acuosa congelada.
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
DE60120936D1 (de) Behandlung von atemerkrankungen
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
HUP0401614A2 (hu) PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina
NO20080950L (no) Topiske formuleringer inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
YU58398A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv
WO2005025498A3 (en) Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
WO2005041922A3 (en) Composition
IS2576B (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
UY28096A1 (es) Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2005011603A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
HRP20050497B1 (en) Use of levocetirizine for the persistent allergic rhinitis
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2005011613A8 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease